Email this article STUDY OF IMMUNOGENICITY AND PROTECTIVEEFFICACY OF A NOVEL INACTIVATEDVACCINE WITH CHITOSAN AGAINST INFLUENZAA/H1N1/2009
- Authors: Loginova SY.1, Shchukina VN1, Borisevich SV1, Bondarev VP1, Markushin SG2, Krivtsov GG2, Mikhaylova NA2, Gendon Y.Z2, Loginova SY.3, Schukina VN3, Borisevich SV3, Bondarev VP3, Markushin SG3, Krivtsov GG3, Mikhaylova NA3, Ghendon Y.Z3
-
Affiliations:
- Branch of 48th Central Research Institute ofMinistry of Defence of RF - Virology Centre,Sergiev Posad
- Mechnikov Research Instituteof Vaccines and Sera, Moscow, Russia
- Issue: Vol 89, No 2 (2012)
- Pages: 51-54
- Section: Articles
- URL: https://microbiol.crie.ru/jour/article/view/13682
- ID: 13682
Cite item
Full Text
Abstract
efficacy of a novel inactivated vaccine with
chitosan against influenza A/H1N1/2009.
Materials and methods. Influenza virus A/
California/7/2009 (H1N1) strain was used in
the study. Mice were immunized twice (21 day
interval) with experimental samples of inactivated
influenza vaccine: No. 1 - without the
addition of chitosan, No. 2 - with addition of
chitosan. The blood was obtained 21 days after
the first and 10 days after the second immunization
with the vaccines and was treated with RDE.
Antibody levels were evaluated in HI reaction.
Results. HI reaction method showed that antibody
titers induced after immunization of vaccine
No. 2 were higher than those induced after
immunization with vaccine No. 1. Eva luation
of protective efficacy of the vaccines against an
experimental form of influenza infection in mice
showed that after immunization with vaccine
that does not contain chitosan the level of virus
accumulation does not differ from the control
statistically significantly (p≤0.05), at the same
time the level of virus accumulation in the lungs
of infected animals immunized with chitosan
containing vaccine significantly (significantly
with 95% probability) decreased by an average
3.0 lg when compared with control. Conclusion.
Comparative analysis of immunogenicity and
protective efficacy of experimental samples of
inactivated influenza vaccine against influenza
A/H1N1/2009 showed that the vaccine with the
addition of chitosan stimulates the formation
of a higher immune response and promotes a
more significant suppression of influenza A
infectious agent reproduction in the lung targetorgan.
About the authors
S Ya Loginova
Branch of 48th Central Research Institute ofMinistry of Defence of RF - Virology Centre,Sergiev PosadBranch of 48th Central Research Institute ofMinistry of Defence of RF - Virology Centre,Sergiev Posad
V N Shchukina
Branch of 48th Central Research Institute ofMinistry of Defence of RF - Virology Centre,Sergiev PosadBranch of 48th Central Research Institute ofMinistry of Defence of RF - Virology Centre,Sergiev Posad
S V Borisevich
Branch of 48th Central Research Institute ofMinistry of Defence of RF - Virology Centre,Sergiev PosadBranch of 48th Central Research Institute ofMinistry of Defence of RF - Virology Centre,Sergiev Posad
V P Bondarev
Branch of 48th Central Research Institute ofMinistry of Defence of RF - Virology Centre,Sergiev PosadBranch of 48th Central Research Institute ofMinistry of Defence of RF - Virology Centre,Sergiev Posad
S G Markushin
G G Krivtsov
N A Mikhaylova
Yu Z Gendon
S Ya Loginova
Mechnikov Research Instituteof Vaccines and Sera, Moscow, RussiaMechnikov Research Instituteof Vaccines and Sera, Moscow, Russia
V N Schukina
Mechnikov Research Instituteof Vaccines and Sera, Moscow, RussiaMechnikov Research Instituteof Vaccines and Sera, Moscow, Russia
S V Borisevich
Mechnikov Research Instituteof Vaccines and Sera, Moscow, RussiaMechnikov Research Instituteof Vaccines and Sera, Moscow, Russia
V P Bondarev
Mechnikov Research Instituteof Vaccines and Sera, Moscow, RussiaMechnikov Research Instituteof Vaccines and Sera, Moscow, Russia
S G Markushin
Mechnikov Research Instituteof Vaccines and Sera, Moscow, RussiaMechnikov Research Instituteof Vaccines and Sera, Moscow, Russia
G G Krivtsov
Mechnikov Research Instituteof Vaccines and Sera, Moscow, RussiaMechnikov Research Instituteof Vaccines and Sera, Moscow, Russia
N A Mikhaylova
Mechnikov Research Instituteof Vaccines and Sera, Moscow, RussiaMechnikov Research Instituteof Vaccines and Sera, Moscow, Russia
Yu Z Ghendon
Mechnikov Research Instituteof Vaccines and Sera, Moscow, RussiaMechnikov Research Instituteof Vaccines and Sera, Moscow, Russia
References
- Васильев Ю.М., Гендон Ю.З. Получение инактивированной вакцины против ви- русов гриппа птиц. Ветеринария. 2010, 4: 58-62.
- Гендон Ю.3. Вакцины и химиопрепараты для профилактики гриппа. Вопр. вирусол. 2007, 52 (1): 4-10.
- Гендон Ю.З., Маркушин С.Г., Кривцов Г.Г. и др. Хитозан как адъювант для инактивированных гриппозных вакцин, вводимых парентерально. Вопр. вирусол. 2008, 5: 831-837.
- Егорова Н.Б., Курбатова Е.А., Семенова И.Б. и др. Влияние хитозана на иммунофенотип и функциональную активность мононуклеарных лейкоцитов мышей при иммунизации инактивированной противогриппозной вакциной. Журн. микробиол. 2008, 6: 31-35.
- Иванушко Л.А., Соловьева Т.Ф., Запорожец Т.С. и др. Сравнительное изучение иммуномодулирующих свойств хитозана и его производных. Мед. иммунол. 2007, 9 (4-5): 397-404.
- Харланов А.В. Влияние хитозана с различной степенью ацетилирования на антителообразование у мышей. Мед. иммунол. 2005, 7 (2-3): C. 329.
- Bright R.A., Medina M.J., Xu X.et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005, 366: 1175-1181.
- Ghendon Y., Markushin S., Vasiliev Y. et al. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J. Med. Virol. 2009, 81 (3): 494-506.
- Gorbach V.I., Krasikova I.N., Luk'yanov P.A. et al. New glycolipids (chitooligosaccharide derivatives) possessing immunostimulating and antitumor activities. Carbohydr. Res. 1994, 260 (1): 73-82.
- http://www.who.int/csr/resources/publications/ swineflu/WHO_OFFLU 2009 _05_15.pdf.
- Sheu T.G., Deyde V.M., Okomo-Adhiambo M. et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Anti microb. Agents Chemother. 2008, 52 (9): 3284-3292.
- Singla A., Chawla M. Chitosan: some pharmaceutical and biological aspects - an update. J. Pharm. Pharmacol. 2001, 53 (8): 1047-1067.
Supplementary files
